The goal of this clinical try is to investigate the effect of hyperbaric oxygen therapy(HBOT) on symptoms, quality of life and absence of work through sickness in patients withpost-COVID on short- and mid-term, as well as to identify biochemical mechanisms ofaction.The main questions it aims to answer are: - What is the clinical relevance of improvements of symptoms and quality of life after treatment with HBOT for post-COVID? - What are the changes in absence from work after treatment with HBOT? - What is the cost-effectiveness of treatment with HBOT? - What are possible mechanisms of action of HBOT?Participants will undergo 40 sessions of HBOT. Researchers will compare HBOT withstandard care alone (control group). In case of a positive outcome, patients in thecontrol group can cross-over to the HBOT group after 6 months.
Not Provided
Drug: Hyperbaric oxygen
Hyperbaric oxygen therapy (2.4 ATA, 40 sessions)
Other Name: HBO,HBOT,Hyperbaric oxygen therapy
Inclusion Criteria:
- Cognitive and/or physical symptoms ≥ 12 months after acute COVID-19 infection
- Symptoms include post-exertional malaise (PEM) and/or dysautonomia as assessed by
questionnaires and/or NASA LEAN test
- Symptoms affect day-to-day life (based on SF-36 'role limitations due to physical
functioning' score of ≤ 50 at baseline).
- Current treatment regimen is stable for at least 1 months before inclusion
Exclusion Criteria:
- Unfit for hyperbaric treatment
- Previous diagnosis of ME/CFS
- Unable to provide informed consent
Da Vinci Clinic
Amersfoort, Netherlands
Da Vinci Clinic
Geldrop, Netherlands
Da Vinci Clinic
Hoogeveen, Netherlands
HGC Rijswijk
Rijswijk, Netherlands
Da Vinci Clinic
Rotterdam, Netherlands
Erasmus MC
Rotterdam, Netherlands
Da Vinci Clinic
Waalwijk, Netherlands
Not Provided